Note 12 - Related Party Transactions

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

(

1

2

)    Related Party Transactions

In

August 2016,

the Company granted an option to purchase

418,977

shares of common stock, with a

4

-year vesting period and an exercise price of

$1.80

per share, to OPKO Health, Inc. (“OPKO”) as consideration for consulting services to be provided by OPKO. BioCardia recorded approximately

$22,000

(as adjusted for the adoption of ASU

2018

-

07

) and

$37,000

as share-based compensation expense related to the OPKO stock option during the

three

months ended

March 31, 2019

and

2018,

respectively. The estimated grant-date fair value of the option was

$5.3

million. The term of the consulting agreement is

4

years and will be automatically renewed for successive

one

year periods. The chairman and chief executive officer of OPKO is a beneficial owner of more than

5%

of the outstanding shares of the Company’s common stock.